Key Concepts: Flagship Biosciences’ MuscleMap algorithm that supports therapeutic development for DMD, a fatal neuromuscular disease, has been validated to be as effective as manual pathology. The study was published in the Archives of Pathology & Laboratory...
Key Concepts: While the current diagnostic strategies for PD-L1 checkpoint inhibitors identify some responders well, the majority of patients still need diagnostic approaches that better predict response. PD-L1 IHC remains a valuable tool for predicting patient...
Key takeaways Understanding the frequency and nature of immune cell clustering is useful in determining patient responses to immunomodulating therapies Flagship’s unique spatial biology services generated a validated computational pathology score that characterized...
Abstract Multiplexed analysis of limited tissue samples can improve our understanding of tumor biology and the tumor microenvironment. Chromogenic and fluorescent multiplexed immunohistochemistry (IHC) approaches are available and offer great insights while conserving...
Abstract Using immunohistochemistry (IHC) to examine immune infiltrates in tissue biopsy samples to support exploratory investigations for immuno-oncology drug development is critical for understanding the abundance and spatial relationships of different immune cell...
Key takeaways The RNAscope® platform enabled duplex chromogenic in situ hybridization (CISH) assay visualization of mRNA targets from multiple cell types and biomarkers Quantification of individual and dual cell positivity within tissue compartments Spatial biology...
Sign up to receive industry and company news, including The Cut Point, Flagship’s quarterly e-newsletter.
NEWS
The Pathologist, September, 2021: Success Through Centralization? The Path to Realizing Digital Pathology’s True ValueBy Flagship Biosciences Team Members: Geoffrey Metcalf, Meredith James, and Roberto GiananiDigital pathology’s benefits have been widely discussed –...
OverviewDuring a recent panel discussion, members of the Flagship Biosciences team and representatives from The Johns Hopkins University, Leap Therapeutics, and Corritori Consulting shared their thoughts on companion diagnostics development, with an emphasis on...
Introduction and BackgroundDr. Roberto Gianani, Chief Medical Officer at Flagship Biosciences, Inc., is a practicing pathologist who is board certified in anatomic pathology, clinical pathology, and pediatric pathology. He is fellowship-trained in surgical pathology...
EVENTS
Visit us at booth 821 at the ASGCT Annual Meeting. We help you analyze more data in more depth, so you can produce more effective therapies. Attending the ASGCT Annual Meeting? Schedule a meeting with our team to discuss our: AI-powered digital pathology solutions...
Visit Us at Booth 2866 in the West Building, Level 2 Flagship Biosciences is your source for spatial biology expertise, moving your research forward every step of the way. Our mission is to explore complex biomarkers within the context of disease in order to advance...
Reuniting 100+ leading experts in biotech, pharma, and academia. February 21-23, 2023. We’re headed to Boston to join other leading experts in biotech, pharma and academia to discuss obstacles in clinical trials and strategies for delivering safer and more effective...